Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study
Abstract
BACKGROUND
Doxycycline is a frequently used alternative treatment for community-acquired pneumonia in hospitalized patients, but the evidence base is limited. The study aimed to compare outcomes in community-acquired pneumonia patients treated with doxycycline or azithromycin in combination with beta-lactams.
METHODS
We evaluated patients with community-acquired pneumonia admitted to Mayo Clinic hospitals from May 2018 to September 2022, treated with either azithromycin or doxycycline in combination with a beta-lactam. Patients who received both antibiotics or were on either as chronic therapy prior to admission were excluded. The primary outcome was mortality. Patients were one-to-one matched according to the presence of congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, human immunodeficiency virus infection, recent immunosuppressant use, and pneumonia severity index class.
RESULTS
Among 8492 patients (5810 for azithromycin, 2682 for doxycycline) 2671 doxycycline-treated patients were matched with azithromycin-treated ones. In hospital mortality was significantly lower in the azithromycin group than in the doxycycline group (odds ratio 0.71; 95% Confidence Interval: 0.56, 0.9), as was 90-day mortality (hazard ratio 0.83= 95% Confidence Interval: 0.73, 0.95). Azithromycin patients also had significantly more hospital free days than those on doxycycline (adjusted estimate=1.37; 95% Confidence Interval: 0.99, 1.74).
CONCLUSIONS
Among…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 8,492 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.